Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
NEW YORK Mcgarrybowen has landed creative duties on Indiplon, a new insomnia drug treatment that will be co-marketed by Pfizer and Neurocrine Biosciences, the agency said.
Billings have not been determined, but competitor Ambien spends approximately $60 million a year on ads.
Mcgarrybowen will develop a consumer marketing strategy and direct-to-consumer ads for the drug, said agency CEO John McGarry.
Doctor-directed ads will be handled by Omnicom Group’s Lyons Lavey Nickel Swift in New York, which was selected after a separate search.
Indiplon
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in